Coherus Oncology, Inc. (CHRS) P/E Ratio History
Deep ValueTrading at -1.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2019–2024
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Coherus Oncology, Inc. (CHRS) trades at a price-to-earnings ratio of -1.0x, with a stock price of $1.48 and trailing twelve-month earnings per share of $-1.11.
The current P/E is 110% below its 5-year average of 9.8x. Over the past five years, CHRS's P/E has ranged from a low of 7.6x to a high of 15.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CHRS trades at a 105% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, CHRS trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CHRS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CHRS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CHRS P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 73.7 | -Best | +158% | |
| $2B | 4.0Lowest | -Best | +1082% | |
| $8B | 19.2 | -Best | +1747%Best | |
| $16B | 47.5 | -Best | -22% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CHRS Historical P/E Data (2019–2024)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2024 Q4 | - | $1.38 | $0.18 | 7.8x | -20% |
| FY2020 Q4 | - | $17.38 | $1.63 | 10.7x | +9% |
| FY2020 Q3 | Sep 30 2020 | $18.34 | $2.04 | 9.0x | -8% |
| FY2020 Q2 | - | $17.86 | $2.34 | 7.6x | -22% |
| FY2020 Q1 | - | $16.22 | $1.96 | 8.3x | -15% |
| FY2019 Q4 | - | $18.00 | $1.19 | 15.1x | +55% |
Average P/E for displayed period: 9.8x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CHRS — Frequently Asked Questions
Quick answers to the most common questions about buying CHRS stock.
What is CHRS's P/E ratio?
Coherus Oncology, Inc. (CHRS) trailing twelve-month P/E ratio is -1.0x, based on TTM diluted EPS of $-1.11. The 5-year average P/E is 9.8x and the historical range spans 7.6x to 15.1x.
Is CHRS stock overvalued or undervalued?
CHRS trades at -1.0x P/E, below its 5-year average of 9.8x. At the 0th percentile of its historical range (7.6x–15.1x), the stock is priced at a discount to its own history.
Is CHRS stock expensive?
No, CHRS is not expensive on a historical basis. The current P/E of -1.0x is below the 5-year average of 9.8x and sits at the 0th percentile of its valuation range.
What is CHRS's historical P/E range?
Over the past 5 years, CHRS's P/E ratio has ranged from 7.6x to 15.1x, with a median of 9.0x and an average of 9.8x. The current P/E of -1.0x places the stock at the 0th percentile of this range. Full historical data spans 2019–2024.
How does CHRS's P/E compare to the S&P 500?
CHRS trades at -1.0x P/E versus the S&P 500 median of 24.4x. The 104% discount to the market suggests lower growth expectations or perceived higher risk.
How does CHRS's valuation compare to Healthcare peers?
Coherus Oncology, Inc. P/E of -1.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CHRS's PEG ratio?
CHRS PEG ratio is N/A, based on a P/E of -1.0x and EPS growth of -680.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CHRS's earnings yield?
CHRS earnings yield is N/A, the inverse of its -1.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.